Related Experiment Video

Updated: Oct 9, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer

Huai-How Ciou1, Tsung-Hsien Lee2, Hsin-Chieh Wang1

  • 1Institute of Medicine, Chung Shan Medical University, Taichung 40203, Taiwan.

Translational Research : the Journal of Laboratory and Clinical Medicine
|December 18, 2021
PubMed

Insights

Gestrinone, an endometriosis drug, may reduce gynecological cancer risk. This study found it inhibited cancer cell growth and induced apoptosis, suggesting potential as a future cancer therapy.

Area of Science:

  • Gynecology
  • Oncology
  • Pharmacology

Background:

  • Endometriosis is linked to increased gynecological cancer risk.
  • The impact of gestrinone, a treatment for endometriosis, on gynecological cancer development is not well-understood.

Purpose of the Study:

  • To investigate the effect of gestrinone on the risk of gynecological cancers in endometriosis patients.
  • To explore the underlying anticancer mechanisms of gestrinone.

Main Methods:

  • Retrospective analysis of Taiwan National Health Insurance Research Database (NHIRD) and Chung Shan Medical University Hospital (CSMUH) data.
  • Correlation analysis between gestrinone use and gynecological cancer incidence.
  • In vitro studies using human cancer cell lines (HeLa) to assess gestrinone's effects on cell growth, apoptosis, and molecular pathways.

Main Results:

  • Endometriosis patients showed a higher risk of ovarian and endometrial cancers, but not cervical cancer.
  • Gestrinone use was associated with a reduced risk of gynecological cancers based on NHIRD and CSMUH data.
  • Gestrinone demonstrated anticancer effects in vitro, inhibiting HeLa cell growth, decreasing P21 expression via JNK phosphorylation, and inducing apoptosis.

Conclusions:

  • Gestrinone shows potential in reducing gynecological cancer risk.
  • The drug's anticancer effects are mediated through the JNK-P21 signaling pathway.
  • Repurposing gestrinone for cancer therapy is a promising future strategy.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.5K